Discovery of New SIRT2 Inhibitors by Utilizing a Consensus Docking/Scoring Strategy and Structure–Activity Relationship Analysis

SIRT2, which is a NAD+ (nicotinamide adenine dinucleotide) dependent deacetylase, has been demonstrated to play an important role in the occurrence and development of a variety of diseases such as cancer, ischemia-reperfusion, and neurodegenerative diseases. Small molecule inhibitors of SIRT2 are thought to be potential interfering agents for relevant diseases. Discovery of SIRT2 inhibitors has attracted much attention recently. In this investigation, we adopted a consensus docking/scoring strategy to screen for novel SIRT2 inhibitors. Structural optimization and structure–activity relationship (SAR) analysis were then carried out on highly potent compounds with new scaffolds, which led to the discovery of 2-((5-benzyl-5<i>H</i>-[1,2,4]­triazino­[5,6-<i>b</i>]­indol-3-yl)­thio)-<i>N</i>-(naphthalen-1-yl)­acetamide (<b>SR86</b>). This compound showed good activity against SIRT2 with an IC₅₀ value of 1.3 μM. <b>SR86</b> did not exhibit activity against SIRT1 and SIRT3, implying a good selectivity for SIRT2. In in vitro cellular assays, <b>SR86</b> displayed very good antiviability activity against breast cancer cell line MCF-7. In Western blot assays, <b>SR86</b> showed considerable activity in blocking the deacetylation of α-tubulin, which is a typical substrate of SIRT2. Collectively, because of the new scaffold structure and good selectivity of <b>SR86</b>, it could serve as a promising lead compound, hence deserving further studies